Walden Biosciences is a biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease. We are developing breakthrough medicines targeted directly to the kidney and will be successful through our comprehensive knowledge and understanding of novel kidney-specific biological pathways and our team’s track record in drug discovery. Our goal is to transform the treatment of kidney disease by reversing its progression, enabling and inspiring patients to resume their normal lives.
Our culture is collaborative and entrepreneurial, and our team is dynamic and driven by data and innovation. We want to make the best decisions with the best available information, lead by example, and bring transformative medicines to patients in need.
Walden is based in the heart of Cambridge, MA between Harvard, Massachusetts Institute of Technology (MIT), and Massachusetts General Hospital.
Location: United States, Massachusetts, Cambridge
Member count: 11-50
Total raised: $51M
Founded date: 2020
Investors 1
| Date | Name | Website |
| - | UCB Ventur... | ucbventure... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 07.10.2020 | Series A | $51M | - | vcnewsdail... |
Mentions in press and media 1
| Date | Title | Description | Category | Author | Source |
| 07.10.2020 | Walden Bio... | CAMBRIDGE, MA, Walden Biosci... | - | - | vcnewsdail... |